Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
The U.S. Food and Drug Administration questioned the differences in size and formulation of the patch used in trials and the to-be-marketed patch. The generic drugs maker, which received a "complete response letter" from the FDA, said it planned to work closely with the agency to address the questions. Such letters typically lay out FDA concerns that need to be addressed before a treatment is approved. Actavis' contraceptive skin patch is designed to provide continuous delivery of the hormone norethindrone, a type of progestin, during a once-weekly, seven-day dosing regimen. Progestin, the synthetic form of female sex hormone progestogen, inhibits ovulation and thickens the layer of mucus at the cervix so sperm cannot enter the uterus. The treatment will compete with Johnson and Johnson's Ortho Evra, an estrogen/progestin combination contraceptive patch. Estrogen is another female sex hormone. A progestin-only patch can be safer than combination patches as high levels of estrogen are often linked to blood clotting disorders and an increased risk of cancer. The company also filed on Tuesday an application to market the generic version of Merck & Co Inc's NuvaRing, a estrogen/progestin combination hormonal contraceptive vaginal ring. Actavis said it may be the first applicant to file the application, which, if approved may entitle it to 180 days of generic market exclusivity. Shares of Dublin, Ireland-based Actavis were down 0.6 percent at $165.16 in early trading on the New York Stock Exchange on Tuesday.

Ex Output:
FDA rejects Actavis' contraceptive patch, seeks more data.

Ex Input:
The decision by Cleveland County District Judge Thad Balkman in Norman, Oklahoma, came in the first case to go to trial out of 2,700 nationally by states, counties and cities seeking to hold drug companies responsible for the deadly epidemic. Balkman reduced the amount he had awarded in August by $107 million after agreeing with New Brunswick, New Jersey-based J&J that he had made a math error. J&J said it will appeal, and that the award and finding of liability were "neither supported by the facts nor the law." A spokesman for Oklahoma Attorney General Mike Hunter said that office is reviewing the decision and will formally respond within the next few days. Opioids were involved in almost 400,000 overdose deaths from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention. Following a non-jury trial, Balkman ruled in August that Oklahoma had proven that J&J engaged in misleading marketing about the benefits of painkillers, and that their addictive risks caused a public nuisance in the form of the opioid crisis. Hunter had sought to have J&J pay $17 billion to help fund addiction treatment and other services to repair damage from the opioid epidemic over the next 30 years. Balkman, however, awarded only enough money for one year of programs, saying Oklahoma failed to support its claims regarding the need to abate the epidemic in future years. Following the August ruling, Oklahoma asked Balkman for permission to return to his courtroom annually to prove those costs, but Balkman on Friday maintained his prior ruling. J&J, meanwhile, argued that it deserved a $355 million credit, reflecting pre-trial settlements by the drugmakers Purdue Pharma LP and Teva Pharmaceutical Industries Ltd. Balkman concluded on Friday that state law did not allow such credits. Last month, J&J and four other companies proposed a $48 billion settlement framework to resolve all of the opioid cases they face, with J&J paying $4 billion. Lawyers for the local governments have opposed the proposal. If approved, the settlement would let J&J resolve some of the thousands of product liability lawsuits it faces. The company also faces litigation over whether its baby powder causes cancer, a claim it denies.

Ex Output:
Oklahoma judge reduces Johnson & Johnson opioid payout to $465 million.

Ex Input:
The company said the trial will continue unchanged as per the recommendation of a data monitoring committee. The trial was testing Bristol-Myers' drugs Opdivo and Yervoy, against Opdivo alone, in patients with advanced melanoma. The combination failed to show a statistically significant benefit in patients whose tumors had 1% or lower levels of the PD-L1 protein being targeted, the company said. The American Cancer Society estimates that about 96,480 melanoma cases will be diagnosed in the United States this year. Bristol-Myers shares were trading at $55.99 before the bell.

Ex Output:
Bristol-Myers misses main goal of late-stage skin cancer trial.